Institution
University of Modena and Reggio Emilia
Education•Modena, Italy•
About: University of Modena and Reggio Emilia is a education organization based out in Modena, Italy. It is known for research contribution in the topics: Population & Medicine. The organization has 8179 authors who have published 22418 publications receiving 671337 citations. The organization is also known as: Università degli Studi di Modena e Reggio Emilia & Universita degli Studi di Modena e Reggio Emilia.
Topics: Population, Medicine, Cancer, Context (language use), Computer science
Papers published on a yearly basis
Papers
More filters
University of Texas MD Anderson Cancer Center1, University of Sydney2, University of Southern California3, University of Modena and Reggio Emilia4, University of Turin5, Katholieke Universiteit Leuven6, University College Dublin7, University of Alberta8, Université libre de Bruxelles9, Vrije Universiteit Brussel10, Bristol-Myers Squibb11
TL;DR: Indirect comparisons suggest combination therapy provides improved efficacy relative to anti-programmed death-1 monotherapy and has a favorable benefit-risk profile.
Abstract: PurposeNivolumab provides clinical benefit (objective response rate [ORR], 31%; 95% CI, 20.8 to 42.9; disease control rate, 69%; 12-month overall survival [OS], 73%) in previously treated patients with DNA mismatch repair–deficient (dMMR)/microsatellite instability–high (MSI-H) metastatic colorectal cancer (mCRC); nivolumab plus ipilimumab may improve these outcomes. Efficacy and safety results for the nivolumab plus ipilimumab cohort of CheckMate-142, the largest single-study report of an immunotherapy combination in dMMR/MSI-H mCRC, are reported.Patients and MethodsPatients received nivolumab 3 mg/kg plus ipilimumab 1 mg/kg once every 3 weeks (four doses) followed by nivolumab 3 mg/kg once every 2 weeks. Primary end point was investigator-assessed ORR.ResultsOf 119 patients, 76% had received ≥ two prior systemic therapies. At median follow-up of 13.4 months, investigator-assessed ORR was 55% (95% CI, 45.2 to 63.8), and disease control rate for ≥ 12 weeks was 80%. Median duration of response was not reac...
1,339 citations
Georgetown University Medical Center1, University of Modena and Reggio Emilia2, Johns Hopkins University3, University of Louisville4, French Institute of Health and Medical Research5, Martin Luther University of Halle-Wittenberg6, University of Miami7, University of Bristol8, Tel Aviv University9, National Institute of Radiological Sciences10
TL;DR: Translocator protein (18kDa) is proposed as a new name, regardless of the subcellular localization of the protein, to represent more accurately its sub cellular role (or roles) and putative tissue-specific function (or functions).
1,264 citations
Duke University1, University of Lausanne2, University of Zurich3, Vita-Salute San Raffaele University4, University of Modena and Reggio Emilia5, University College London6, Catholic University of the Sacred Heart7, King's College London8, Murdoch University9, University of Barcelona10, University of Copenhagen11, University of Geneva12, Harvard University13, John Radcliffe Hospital14
TL;DR: Using a whole-genome association strategy, polymorphisms that explain nearly 15% of the variation among individuals in viral load during the asymptomatic set-point period of infection are identified.
Abstract: Understanding why some people establish and maintain effective control of HIV-1 and others do not is a priority in the effort to develop new treatments for HIV/AIDS. Using a whole-genome association strategy, we identified polymorphisms that explain nearly 15% of the variation among individuals in viral load during the asymptomatic set-point period of infection. One of these is found within an endogenous retroviral element and is associated with major histocompatibility allele human leukocyte antigen (HLA)-B*5701, whereas a second is located near the HLA-C gene. An additional analysis of the time to HIV disease progression implicated two genes, one of which encodes an RNA polymerase I subunit. These findings emphasize the importance of studying human genetic variation as a guide to combating infectious agents.
1,230 citations
Vilnius University1, University of Ferrara2, Aarhus University3, University of Oslo4, Royal Institute of Technology5, Electromagnetic Geoservices6, University of Trieste7, Norwegian Computing Center8, University of Southern Denmark9, University of Santiago de Compostela10, Danske Bank11, Ruhr University Bochum12, Norwegian Meteorological Institute13, Norwegian Defence Research Establishment14, University of Auckland15, Norwegian University of Science and Technology16, Information Technology University17, Technical University of Ostrava18, Linköping University19, Karlsruhe Institute of Technology20, ETH Zurich21, Australian National University22, University of Modena and Reggio Emilia23, Cisco Systems, Inc.24, University of Buenos Aires25, University of Copenhagen26, University of Erlangen-Nuremberg27, Kazimierz Wielki University in Bydgoszcz28, National Scientific and Technical Research Council29, University of Valencia30, Paul Sabatier University31, University of Melbourne32, University of Nottingham33, University of Bristol34, CLC bio35, Princeton University36, La Trobe University37, Clemson University38
TL;DR: Dalton is a powerful general‐purpose program system for the study of molecular electronic structure at the Hartree–Fock, Kohn–Sham, multiconfigurational self‐consistent‐field, Møller–Plesset, configuration‐interaction, and coupled‐cluster levels of theory.
Abstract: Dalton is a powerful general-purpose program system for the study of molecular electronic structure at the Hartree-Fock, Kohn-Sham, multiconfigurational self-consistent-field, MOller-Plesset, confi ...
1,212 citations
University of Rome Tor Vergata1, Dresden University of Technology2, University of Bari3, Catholic University of the Sacred Heart4, University of Hamburg5, Sapienza University of Rome6, Casa Sollievo della Sofferenza7, University of Freiburg8, University of Cagliari9, University of Modena and Reggio Emilia10, Vita-Salute San Raffaele University11, University of Ulm12, Hannover Medical School13
TL;DR: ATRA plus arsenic trioxide is at least not inferior and may be superior to ATRA plus chemotherapy in the treatment of patients with low-to-intermediate-risk APL.
Abstract: Background All-trans retinoic acid (ATRA) with chemotherapy is the standard of care for acute promyelocytic leukemia (APL), resulting in cure rates exceeding 80%. Pilot studies of treatment with arsenic trioxide with or without ATRA have shown high efficacy and reduced hematologic toxicity. Methods
1,184 citations
Authors
Showing all 8322 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Carlo M. Croce | 198 | 1135 | 189007 |
| Gregory Y.H. Lip | 169 | 3159 | 171742 |
| Geoffrey Burnstock | 141 | 1488 | 99525 |
| Peter M. Rothwell | 134 | 779 | 67382 |
| Claudio Franceschi | 120 | 856 | 59868 |
| Lorenzo Galluzzi | 118 | 477 | 71436 |
| Leonardo M. Fabbri | 109 | 566 | 60838 |
| David N. Reinhoudt | 107 | 1082 | 48814 |
| Stefano Pileri | 100 | 635 | 43369 |
| Andrea Bizzeti | 99 | 1168 | 46880 |
| Brian K. Shoichet | 98 | 281 | 40313 |
| Dante Gatteschi | 97 | 727 | 48729 |
| Roberta Sessoli | 95 | 424 | 41458 |
| Thomas A. Buchholz | 93 | 494 | 33409 |
| Pier Luigi Zinzani | 92 | 857 | 35476 |